Videos

Ophthalmology experiences lower burnout rates compared with other medical fields, but the profession is not immune to the issue, explains Peter J. McDonnell, MD.

Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.

At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.

Edward J. Holland, MD, and Professor Shigeru Kinoshita, MD, discuss how a single donor cornea could potentially help over a thousand patients.

David Hutton of Ophthalmology Times spent time with Esen K Akpek, MD, who discussed her presentation at this year's American Academy of Ophthalmology meeting.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Lisa M. Nijm, MD, JD, discusses the action-packed agenda of Real World Ophthalmology’s virtual event on September 30, 2023.

Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

Our team spoke with several researchers and industry professionals at the 2023 American Society of Retina Specialists meeting in Seattle, Washington. We asked them, "What research here do you find exciting or interesting?" Here's what Tarek Hassan, MD, Nancy Lurker, and J. Fernando Arevalo, MD, PhD, FACS, FASRS, had to say.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say.

Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team about clinical characteristics of macular holes that close without surgery at the 2023 ASRS annual meeting.

Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.

Aleksandra Rachiskaya, MD, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept at the 2023 ASRS annual meeting.

Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.

Russ Trenary, President and CEO at Outlook Therapeutics spoke with our team to share information on the company's work toward FDA approval for Bevacizumab at the 2023 ASRS annual meeting.